August 5, 2022
Shionogi said on August 4 that it has entered into a license deal to commercialize Grünenthal’s injectable resiniferatoxin in Japan for the treatment of pain in patients with osteoarthritis of the knee. Resiniferatoxin is a highly potent transient receptor potential...read more